A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Clinical trial NCT06007690 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06007690
Sponsor: Aura Biosciences
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Choroidal Melanoma Indeterminate Lesions Uveal Melanoma Ocular Melanoma

Start date: 2023-12-06
Primary completion: 2027-11-15
Enrollment: 108

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.